Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

Zurück
17 September 2018, 13:42
920

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine - Bild 1

September 14, became known that the pharmaceutical company ViiV Healthcare, part of the GlaxoSmithKline structure, applied to the European Medicines Agency (EMA) for the registration of a two-component antiretroviral dolutegravir / lamivudine intended for the treatment of patients with HIV-1.

As reported by the portal PharmaTimes, the basis for filing documents for registration were the recently announced results of the GEMINI 1 and 2 studies, which managed to confirm the efficacy of the drug comparable with the three-component scheme.

The developers of the combination explain that the overall rate of patients who achieved undetectable viral load in studies exceeded 90%.

At the same time, the number of those who stopped taking therapy against the background of side effects did not exceed 2%. At the same time, as stressed in ViiV, the number of undesirable reactions in dolutegravir / lamivudine patients was significantly less than in cases with three components (18% and 24%, respectively).

We add that ViiV confirmed its intention to apply for registration of the drug in the US in October. The developer is counting on an accelerated procedure.

Teilen Sie in sozialen Netzwerken